Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Articles|February 1, 2010
Topics
Addiction medicineAddictive behaviorAIDS dementia complexAkinetic mutismAlcoholic psychosesAlzheimer diseaseAmnesiaAmphetamine-related disordersAmyotrophic lateral sclerosisAntisocial personality disorderAnxiety disordersAttention deficit and disruptive behavior disordersAttention deficit hyperactivity disorderAutismAutistic disorder
Advertisement
Advertisement
Related to this article
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
Brenipatide for Alcohol Use Disorder: Emerging Findings
4
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
5